Skip to main content
SpringerLink
Log in
Book cover

Antibody-Drug Conjugates and Immunotoxins pp 139–147Cite as

Antibody–Drug Conjugates for the Treatment of B-Cell Malignancies

  • Chapter
  • First Online:

  • 2530 Accesses

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Abstract

Malignancies of B-cell origin constitute a diverse set of neoplasms that vary in B-cell subtype of origin and underlying genetic drivers. In addition, they vary widely in clinical outcome. Follicular non-Hodgkin’s lymphoma (FL) or chronic lymphocytic leukemia (CLL), are indolent and incurable diseases with a median survival of 8–10 years whereas the more aggressive diseases such as diffuse large cell lymphoma (DCBL) and Mantle cell lymphoma (MCL) can have a median survival of 6 months if left untreated. Diffuse large B-cell lymphoma (DLBCL) is the most common type of NHL accounting for approximately 30–40 % of all NHL diagnosis followed by follicular lymphoma (20–25 % of NHL diagnosis) and MCL (6–10 % NHL diagnosis). B-cell chronic lymphocytic leukemia (B-CLL) is the most common of the chronic leukemias in adults with approximately 15,000 new cases per year in the United States [1]. These diseases are quite diverse; however, most of them are treated with the anti-CD20 chimeric monoclonal antibody rituximab (Rituxan®, MabThera®) in combination with cytotoxic chemotherapy. Although durable responses can be achieved in some patients, approximately half of patients with aggressive NHL will ultimately experience progressive or relapsed disease. In addition, indolent B-cell malignancies remain incurable despite longer durations of response with current therapies. Thus, there is still a need for treatments that can significantly extend disease-free and overall survival in these patients, with at least acceptable if not superior safety profiles.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225–249

    Article  PubMed  Google Scholar 

  2. Solal-Celigny P (2006) Safety of rituximab maintenance therapy in follicular lymphomas. Leuk Res 30(Suppl 1):S16–S21

    Article  PubMed  CAS  Google Scholar 

  3. Billadeau DD, Leibson PJ (2002) ITAMs versus ITIMs: striking a balance during cell regulation. J Clin Invest 109(2):161–168

    PubMed  CAS  Google Scholar 

  4. Tedder TF, Tuscano J, Sato S, Kehrl JH (1997) CD22, a B lymphocyte-specific adhesion ­molecule that regulates antigen receptor signaling. Annu Rev Immunol 15:481–504

    Article  PubMed  CAS  Google Scholar 

  5. Polson AG, Williams M, Gray AM et al (2010) Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin’s lymphoma. Leukemia 24(9):1566–1573

    Article  PubMed  CAS  Google Scholar 

  6. DiJoseph JF, Armellino DC, Boghaert ER et al (2004) Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 103(5):1807–1814

    Article  PubMed  CAS  Google Scholar 

  7. Zein N, Poncin M, Nilakantan R, Ellestad GA (1989) Calicheamicin gamma 1I and DNA: molecular recognition process responsible for site-specificity. Science 244(4905):697–699

    Article  PubMed  CAS  Google Scholar 

  8. Dang N, Smith M, Offner F et al (2009) Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544)  +  rituximab: clinical activity including survival in patients with recurrent/refractory follicular or ‘aggressive’ lymphoma. Blood (ASH Annual Meeting Abstracts) 114(22):Abstract 584

    Google Scholar 

  9. Fayad L, Patel H, Verhoef G et al (2008) Safety and clinical activity of the anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) in combination with rituximab in follicular lymphoma or diffuse large B-cell lymphoma: preliminary report of a phase 1/2 study. ASH Annu Meet Abstr 112(11):266

    Google Scholar 

  10. Ogura M, Tobinai K, Hatake K et al (2010) Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. Cancer Sci 101(8):1840–1545

    Article  PubMed  CAS  Google Scholar 

  11. Ogura M, Uchida T, MacDonald DA et al (2011) An open-label, Phase I Study of R-CVP in combination with inotuzumab ozogamicin in patients with relapsed/refractory CD22-positive B-cell non-Hodgkin lymphoma. ASH Annu Meet Abstr 118(21%U http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;118/21/3715 %8 November 18, 2011):3715

  12. Advani A, Coiffier B, Czuczman MS et al (2010) Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin’s lymphoma: results of a phase I study. J Clin Oncol 28(12):2085–2093

    Article  PubMed  CAS  Google Scholar 

  13. Younes A, Gordon L, Kim S et al (2009) Phase I multi-dose escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous (IV) infusion every 3 weeks to patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL). ASH Annu Meet Abstr 114(22):585

    Google Scholar 

  14. Barclay AN, Brown M, Law SKA, McKinght AJ, Tomlinson MG, Anton van der Merwe P (1997) The leucocyte antigen facts book. Academic, San Diego, CA

    Google Scholar 

  15. Olejniczak SH, Stewart CC, Donohue K, Czuczman MS (2006) A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. Immunol Invest 35(1):93–114

    Article  PubMed  CAS  Google Scholar 

  16. Coiffier B, Ribrag V, Dupuis J et al (2011) Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients (pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). ASCO Meet Abstr 29(Suppl 15):8017

    Google Scholar 

  17. Raponi S, Stefania De Propris M, Intoppa S et al (2011) Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma 52(6):1098–1107

    Article  PubMed  CAS  Google Scholar 

  18. O’Brien S, Thomas DA, Ohanian M et al (2011) Inotuzumab Ozogamycin (I0), a CD22 monoclonal antibody conjugated to calecheamicin, is active in refractory-relapse acute lymphocytic leukemia (R-R ALL). ASH Annu Meet Abstr 118(21):875

    Google Scholar 

  19. Arens R, Schepers K, Nolte MA et al (2004) Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation. J Exp Med 199(11):1595–1605

    Article  PubMed  CAS  Google Scholar 

  20. Lens SM, Drillenburg P, den Drijver BF et al (1999) Aberrant expression and reverse signalling of CD70 on malignant B cells. Br J Haematol 106(2):491–503

    Article  PubMed  CAS  Google Scholar 

  21. Oflazoglu E, Stone IJ, Gordon K et al (2008) Potent anticarcinoma activity of the humanized anti-CD70 antibody h1f6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin Cancer Res 14(19):6171–6180

    Article  PubMed  CAS  Google Scholar 

  22. Wischhusen J, Jung G, Radovanovic I et al (2002) Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res 62(9):2592–2599

    PubMed  CAS  Google Scholar 

  23. Alley SC, Benjamin DR, Jeffrey SC et al (2008) Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem 19(3):759–765

    Article  PubMed  CAS  Google Scholar 

  24. Derwin D, Passmore D, Sung J et al (2010) Activation of antibody drug conjugate MDX-1203 by human carboxylesterase. Meeting of the American Association for Cancer Research

    Google Scholar 

  25. Alberts SR, Erlichman C, Reid JM et al (1998) Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks. Clin Cancer Res 4(9):2111–2117

    PubMed  CAS  Google Scholar 

  26. Gerber H-P, Kung-Sutherland M, Stone I et al (2009) Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas. Blood 113(18):4352–4361

    Article  PubMed  CAS  Google Scholar 

  27. Rao C, Pan C, Vangipuram R et al (2010) Efficacy and toxicity of an anti-CD19 antibody drug conjugate. Annual Meeting of the American Association for Cancer Research, Washington, DC, p. 2452

    Google Scholar 

  28. Sharkey RM, Govindan SV, Cardillo TM, Goldenberg DM (2012) Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies. Mol Cancer Ther 11(1):224–234

    Article  PubMed  CAS  Google Scholar 

  29. Leonard JP, Goldenberg DM (2007) Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. Oncogene 26(25):3704–3713

    Article  PubMed  CAS  Google Scholar 

  30. Traczewski P, Rudnicka L (2011) Treatment of systemic lupus erythematosus with epratuzumab. Br J Clin Pharmacol 71(2):175–182

    Article  PubMed  CAS  Google Scholar 

  31. Dijoseph JF, Dougher MM, Armellino DC et al (2007) CD20-specific antibody-targeted chemotherapy of non-Hodgkin’s B-cell lymphoma using calicheamicin-conjugated rituximab. Cancer Immunol Immunother 56(7):1107–1117

    Article  PubMed  CAS  Google Scholar 

  32. Law C-L, Cerveny CG, Gordon KA et al (2004) Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates. Clin Cancer Res 10(23):7842–7851

    Article  PubMed  CAS  Google Scholar 

  33. Polson AG, Calemine-Fenaux J, Chan P et al (2009) Antibody-drug conjugates for the treatment of non-Hodgkin’s lymphoma: target and linker-drug selection. Cancer Res 69(3):2358–2364

    Article  PubMed  CAS  Google Scholar 

  34. Krop IE, Beeram M, Modi S et al (2010) Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 28(16):2698–2704

    Article  PubMed  CAS  Google Scholar 

  35. Zheng B, Fuji RN, Elkins K et al (2009) In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates. Mol Cancer Ther 8(10):2937–2946

    Article  PubMed  CAS  Google Scholar 

  36. Dornan D, Bennett F, Chen Y et al (2009) Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood 114(13):2721–2729

    Article  PubMed  CAS  Google Scholar 

  37. Polson AG, Yu SF, Elkins K et al (2007) Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood 110(2):616–623

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Genentech Research and Early Development, 1 DNA Way, South San Francisco, CA, 94080, USA

    Andrew G. Polson

Authors
  1. Andrew G. Polson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew G. Polson .

Editor information

Editors and Affiliations

  1. DNA Way 1, South San Francisco, 94080, California, USA

    Gail Lewis Phillips

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Polson, A.G. (2013). Antibody–Drug Conjugates for the Treatment of B-Cell Malignancies. In: Phillips, G. (eds) Antibody-Drug Conjugates and Immunotoxins. Cancer Drug Discovery and Development. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5456-4_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-5456-4_8

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-5455-7

  • Online ISBN: 978-1-4614-5456-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation